结直肠癌的免疫治疗

IF 2.7 Q3 ONCOLOGY

Colorectal Cancer Pub Date : 2017-06-21 DOI:10.2217/CRC-2017-0002

A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb

{"title":"结直肠癌的免疫治疗","authors":"A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb","doi":"10.2217/CRC-2017-0002","DOIUrl":null,"url":null,"abstract":"The evidence that the immune system, when rightly stimulated, can eradicate cancer cells, combined with the latest knowledge about antitumor immunity, has led to recent progress in cancer immunotherapy. While infiltration of tumors with immune cells is described in advanced stage colorectal cancer (CRC), the first data concerning the clinical efficacy of immune-targeted therapies in CRC patients were disappointing. The evidence of tumor responses in CRC patients with microsatellite instability treated with immune checkpoint blockers has renewed the interest for research in the field of CRC immunotherapy. In this article, we briefly review the role of T lymphocytes infiltrating CRC tumors in order to introduce a brief history of CRC immunotherapy and then current trials involving immune-based strategies and particularly immune checkpoint blockers.","PeriodicalId":43638,"journal":{"name":"Colorectal Cancer","volume":"6 1","pages":"1-10"},"PeriodicalIF":2.7000,"publicationDate":"2017-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/CRC-2017-0002","citationCount":"4","resultStr":"{\"title\":\"Immune therapy in colorectal cancer\",\"authors\":\"A. Lapeyre-Prost, M. Terme, S. Pernot, E. Marcheteau, Anne-Laure Pointet, T. Voron, E. Tartour, J. Taieb\",\"doi\":\"10.2217/CRC-2017-0002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The evidence that the immune system, when rightly stimulated, can eradicate cancer cells, combined with the latest knowledge about antitumor immunity, has led to recent progress in cancer immunotherapy. While infiltration of tumors with immune cells is described in advanced stage colorectal cancer (CRC), the first data concerning the clinical efficacy of immune-targeted therapies in CRC patients were disappointing. The evidence of tumor responses in CRC patients with microsatellite instability treated with immune checkpoint blockers has renewed the interest for research in the field of CRC immunotherapy. In this article, we briefly review the role of T lymphocytes infiltrating CRC tumors in order to introduce a brief history of CRC immunotherapy and then current trials involving immune-based strategies and particularly immune checkpoint blockers.\",\"PeriodicalId\":43638,\"journal\":{\"name\":\"Colorectal Cancer\",\"volume\":\"6 1\",\"pages\":\"1-10\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2017-06-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.2217/CRC-2017-0002\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Colorectal Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/CRC-2017-0002\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colorectal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/CRC-2017-0002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 4

摘要

有证据表明，免疫系统在适当的刺激下可以根除癌细胞，再加上抗肿瘤免疫的最新知识，导致了癌症免疫治疗的最新进展。虽然在晚期结直肠癌(CRC)中描述了免疫细胞浸润肿瘤，但有关免疫靶向治疗在CRC患者中的临床疗效的初步数据令人失望。免疫检查点阻断剂治疗结直肠癌微卫星不稳定患者的肿瘤应答的证据重新引起了结直肠癌免疫治疗领域的研究兴趣。在本文中，我们简要回顾了T淋巴细胞浸润结直肠癌肿瘤的作用，以介绍结直肠癌免疫治疗的简史，以及目前涉及免疫策略的试验，特别是免疫检查点阻断剂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Immune therapy in colorectal cancer

The evidence that the immune system, when rightly stimulated, can eradicate cancer cells, combined with the latest knowledge about antitumor immunity, has led to recent progress in cancer immunotherapy. While infiltration of tumors with immune cells is described in advanced stage colorectal cancer (CRC), the first data concerning the clinical efficacy of immune-targeted therapies in CRC patients were disappointing. The evidence of tumor responses in CRC patients with microsatellite instability treated with immune checkpoint blockers has renewed the interest for research in the field of CRC immunotherapy. In this article, we briefly review the role of T lymphocytes infiltrating CRC tumors in order to introduce a brief history of CRC immunotherapy and then current trials involving immune-based strategies and particularly immune checkpoint blockers.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Colorectal Cancer ONCOLOGY-

自引率

0.00%

发文量

期刊介绍： Colorectal cancer is a major cause of morbidity and mortality, particularly in the developed world. Risk factors for colorectal cancer are on the rise in many countries; populations are aging, and obesity and diabetes are increasing. National screening programs are helping to detect cancer while it is still curable; however, colorectal cancer remains the third leading cause of cancer deaths in the USA and options are still limited for those with more advanced disease. Consequently, colorectal cancer is a major research priority for government, pharmaceutical companies and non-profit organizations. Research into diagnosis and optimum treatment of the disease is progressing rapidly, with new advances reported every day. Colorectal Cancer presents reviews, analysis and commentary. on all aspects of colorectal cancer.